Yuanzhi three-eyed creature (元智三目生物)
Bei Jing Shi, China
The company utilizes medical big data and intestinal metagenomics, combining various artificial intelligence technologies with microbial culture and analysis tools to create a closed loop of wet and dry experiments. It has established an A3M technology research and development platform that integrates "artificial intelligence (AI) + multi-omics + medicine + microbiology" to enhance the discovery of new functional genes and strains within intestinal flora. The company focuses on accurately identifying target groups and designing multi-strain formulas to improve the success rates of microbial preparations and drug discovery. Currently, it is engaged in strain transformation for hyperuricemia and non-alcoholic fatty liver disease and is developing probiotics for human use and microecological preparations for animals.
Company Info
- Founded
- 2022
- Website
- a3mlab.com/
Only accessible to MedStartr community members.
Join nowWhat do you think of Yuanzhi three-eyed creature (元智三目生物)?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.